Startup Poland is pleased to present you with the first report on Digital Health
This report has been produced following an in-depth analysis of data gathered from innovative startup companies operating on the Polish market to offer insight into the current state of high-tech companies in the field of medicine. It fosters a better understanding of the environment, barriers, and opportunities for companies focusing on digital health.
1. 84 percent of startups plan to expand their operations into new international markets within the coming 12 months.
The vast majority of Polish startups in the digital health industry (84 percent) are planning to expand their operations into a new international market in the coming 12 months, with Western Europe being the most common direction and in the crosshairs of 75 percent of study participants. Northern America ranks second at 42%, and the Middle East is indicated by 31% of responses. What’s interesting is that only 22 percent of startups intend to expand into a new market in our region in the near future.
2. Primary barriers to cooperation with government institutions include bureaucracy and extensive legislative processes.
Support from the public sector and administrative and legal facilitation to support the development of innovation help the development of startups in Poland. However, there are still difficulties resulting from intellectual property valuation, patenting, complicated administrative procedures, or shortcomings in the environment supporting commercialization.
3. Key scopes of cooperation with business partners include marketing support and validation of business assumptions.
While not every startup in the digital health sector gets engaged in research and development activities, embarking on cooperation with universities, scientists, researchers, or other entities which allow them to take advantage of scientific knowledge and support, if they want to function in the market they usually have to work with commercial partners.
4. Startups are more willing to work directly with scientists than with universities. Nearly half of all MedTech companies work with individual scientists who support their research and development efforts.
5. Half of the startups do not own any patents and they are not in the process of obtaining any.
Patents that protect intellectual property and limit the risk of ideas being copied by competing entities may be the foundation for rapid business development, but it’s not always possible to obtain this level of protection.
6. Startups use a broad range of financing options, more than half of them reach out for National Center for Research and Development resources.
Grants awarded in contests, transferred through Venture Capital funds and investments by the latter are the most popular support instruments of NCBR.
Support, not only financial but can also be obtained from the VC or CVC (corporate venture capital) funds launched by us in the BRIdge fund family. More than 50 BRIdge Alfa funds are currently conducting investment activity in the seed funding segment - this is the second most popular source of financing for MedTech start-ups. "Alfa funds” seek the best ideas of scientists and entrepreneurs and support them at seed and preseed stages of development, when the risk of failure is the greatest.
7. The medical specialization of MedTech startups varies. The main field is cardiology (31%), and psychology comes second (23%).
8. The IT solutions used by Polish MedTech companies include mostly remote technologies: telemedicine, mobile applications (mhealth), and web applications.
9. Target groups which the digital health solutions are aimed at are also differentiated, with a dominant position occupied by healthcare services, hospitals, and doctors
10. Less than 1/4 who run Digital Health startups studied medical science.
National Centre for Research and Development
The National Center for Research and Development (NCBR) is a government agency supporting projects aimed at economic and social development.
Through grants and other mechanisms, such as venture capital funds, NCBR finances R&D projects of enterprises and research units as well as university activities aimed at improving the quality of education and developing technological competencies.
With an annual budget for R&D of EUR 1 billion, NCBR is currently the largest center for supporting the development of science and economy in the country and the region.
Roche Poland is a leader among companies providing innovative solutions in the field of health protection.
For over 100 years, Roche has been supporting Polish doctors in their daily fight for the health and life of patients, and also cooperates with academic and medical communities. Roche's global strategy focuses on molecular diagnostics and targeted therapies. Roche has a modern and unique portfolio in such therapeutic fields as oncology, nephrology, transplantology, rheumatology, neurology, cardiology, and infectious diseases.
By submitting your name and e-mail address you grant Startup Poland with a permission to store, process and share your data with third-party services, including the website hosting service company, Strikingly Inc. Specifically, you grant us permission to send you email messages. You may revoke these permissions at any time by emailing your request to: email@example.com